Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements

The combination of dabrafenib and trametinib is a well-established treatment for BRAF-mutated melanoma. However, the effectiveness of this approach may be hindered by the development of treatment-related pyrexia syndrome, which occurs in at least 50% of treated patients. Without appropriate interven...

Description complète

Détails bibliographiques

Auteurs principaux:	Alia Thawer, Wilson H. Miller, Nancy Gregorio, Joël Claveau, Sudha Rajagopal, Kerry J. Savage, Xinni Song, Teresa M. Petrella, on behalf of the Canadian Working Group
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2021-09-01
Collection:	Current Oncology
Sujets:	melanoma pyrexia dabrafenib trametinib
Accès en ligne:	https://www.mdpi.com/1718-7729/28/5/304
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!